Burning Rock Announces Founder’s Purchase of Its ADSs

Rhea-AI Summary

Burning Rock (NASDAQ: BNR) announced on Jan 5, 2026 that its founder, chairman and CEO Yusheng Han purchased US$811,721.28 of the company’s ADSs from the open market.

The company said the purchases were executed in compliance with applicable rules, the company’s insider trading policy, and may be continued through open-market transactions, privately negotiated trades or block trades depending on market conditions. The announcement notes timing will follow Rule 10b-18 and Rule 10b5-1 requirements and company policy.

Positive

• Founder purchased $811,721.28 of ADSs on Jan 5, 2026

Negative

• None.

Key Figures

Founder ADS purchase value US$811,721.28 Open-market purchases by founder/CEO as of press release date

Market Reality Check

$24.48 Last Close

Volume Volume 32,138 is 0.56x the 20-day average of 56,996 shares. low

Technical Price 19.68 is trading above the 200-day MA at 8.25.

Peers on Argus

Key diagnostics peers like FONR, PRE, BDSX, MDXH, and XGN show modest declines (e.g., -0.24% to -4.72%), broadly consistent with BNR’s -2.33% move but without momentum-scanner confirmation of a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 22	Annual meeting results	Neutral	+7.8%	All 2025 AGM resolutions passed, including auditor ratification and director re-elections.
Dec 01	AGM announcement	Neutral	-12.0%	Announcement and agenda for 2025 AGM and reference to filed Form 20-F.
Nov 20	Q3 2025 earnings	Positive	-3.1%	Q3 revenue growth, margin improvement, and narrowed net loss with solid cash balance.
Sep 24	Japan CDx approval	Positive	-0.8%	MHLW approval in Japan for OncoGuide OncoScreen Plus CDx in breast cancer.
Sep 08	Q2 2025 earnings	Positive	+9.2%	Q2 revenue growth, strong pharma R&D expansion, lower opex, sharply reduced net loss.

Pattern Detected

Positive operational or financial updates have sometimes led to negative or muted next-day moves, while some routine governance items have coincided with sharp gains or losses.

Recent Company History

Over the past months, Burning Rock reported improving financials, including Q2 and Q3 2025 results with higher revenues, expanding gross margins, and a narrowed net loss, alongside strong growth in pharma R&D revenue. It also secured MHLW approval in Japan for the OncoGuide OncoScreen Plus CDx system. Corporate governance events such as the Dec. 22, 2025 AGM and its prior announcement showed mixed price reactions. Today’s founder ADS purchase adds an insider confidence signal to this backdrop of gradual operational improvement.

Market Pulse Summary

The stock surged +24.4% in the session following this news. A strong positive reaction aligns with the signal of insider confidence from the founder’s open‑market ADS purchases totaling US$811,721.28. Past news showed mixed price alignment, with some positive operational updates followed by weak moves. Investors could weigh whether this insider buying, combined with prior improvements in revenue and margins, represents a durable re‑rating or risks a pullback if enthusiasm fades.

Key Terms

ads financial

"has purchased US$811,721.28 of the Company’s ADSs from the open market"

Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.

next generation sequencing medical

"focusing on the application of next generation sequencing (NGS) technology"

A collection of advanced laboratory methods that read and map large amounts of DNA or RNA quickly and at lower cost than older techniques; think of it as scanning thousands of pages of a book at once instead of reading one page at a time. Investors care because it accelerates drug development, enables precise diagnostics and personalized treatments, and can create recurring revenue from tests, instruments, and data services as adoption expands.

precision oncology medical

"technology in the field of precision oncology"

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

rule 10b-18 regulatory

"including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities"

Rule 10b-18 is a regulation that sets strict rules for how a company's executives and employees can buy back their own company's stock from the market. It helps ensure that these buybacks happen in a fair and transparent way, reducing the chance of market manipulation. This is important for investors because it offers protection against unfair practices and promotes confidence in the integrity of the stock market.

rule 10b5-1 regulatory

"including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

insider trading policy regulatory

"in accordance with the applicable rules and regulations and the Company’s insider trading policy"

A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.

AI-generated analysis. Not financial advice.

GUANGZHOU, China, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that as of the date of this press release, its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased US$811,721.28 of the Company’s ADSs from the open market, which was conducted in compliance with the applicable rules and regulations and the Company’s insider trading policy. Mr. Han’s purchase of the Company’s ADSs indicates his confidence in the Company’s business and prospect.

Mr. Han may continue to purchase the Company’s ADSs through open-market transactions, privately negotiated transactions or block trades, or other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of Mr. Han’s purchase will be subject to various factors, including the requirements under Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934, as well as the Company’s insider trading policy.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Contact: IR@brbiotech.com

FAQ

What did Burning Rock (BNR) announce on January 5, 2026 about insider buying?

Burning Rock said founder and CEO Yusheng Han purchased $811,721.28 of the company’s ADSs from the open market.

How was Yusheng Han’s January 5, 2026 ADS purchase by BNR conducted?

The company stated the purchase was made on the open market in compliance with applicable rules and the company’s insider trading policy.

Could BNR CEO Yusheng Han buy more ADSs after January 5, 2026?

Yes. The company said Mr. Han may continue to purchase ADSs via open-market, private or block trades subject to rules and company policy.

What regulatory rules did Burning Rock cite for the CEO’s ADS purchases (BNR)?

The announcement referenced compliance with Rule 10b-18 and Rule 10b5-1 of the Securities Exchange Act of 1934 and the company’s insider trading policy.

Does the January 5, 2026 purchase by Burning Rock’s founder indicate confidence in BNR business?

The company said the founder’s purchase indicates his confidence in the company’s business and prospects.